News GLP-1s feature in second batch of national priority vouchers GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.
News Dismay as FDA declines to approve Biohaven's ataxia drug Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, in another sign of a tougher stance by the agency.
R&D Biotech’s biggest challenge isn’t scientific, but political ... We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR
News CDER head Tidmarsh 'on leave' and is sued by drugmaker George Tidmarsh is no longer at the helm of CDER and is facing a lawsuit claiming he abused his position there to harm a former business associate.
News FDA plan will cut testing requirements for biosimilars The FDA has proposed a radical change to the regulatory requirements for bringing biosimilar medicines to market as a way to cut US drug prices.
News FDA hands out first national priority vouchers to nine firms The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher programme.
Oncology Getting predictive technologies to patients, with Concr Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.